항바이러스제 시장 : 시장 규모, 점유율, 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of antiviral drugs Market

The global antiviral drugs market is expected to experience steady growth over the forecast period. In 2025, the market was valued at USD 42.34 billion, projected to reach USD 44.21 billion in 2026, and expand to USD 54.37 billion by 2034, representing a CAGR of 3.64% from 2026-2034. North America dominated the market in 2025 with a 38.78% share, attributed to the presence of leading pharmaceutical companies, high prevalence of viral infections such as HIV, and multiple USFDA drug approvals.

Viruses are infectious particles containing RNA or DNA enclosed in a protein coat, capable of infecting human cells and causing viral diseases. Viral infections are a significant public health concern, responsible for considerable morbidity and mortality. Antiviral drugs work by inhibiting viral replication or restoring the normal function of host cells. With over a thousand viruses infecting humans and accounting for approximately 60% of human infections, the demand for effective antiviral therapies remains high. However, rapid virus replication and lack of quick diagnostic reagents present challenges in drug development.

Market Drivers

The market is primarily driven by the rising prevalence of HIV and influenza globally. According to WHO, approximately 37.9 million people were living with HIV in 2018, with 770,000 deaths attributed to the disease. Enhanced HIV surveillance and improved diagnostic tools have expanded the patient pool for antiretroviral therapies. Similarly, the rapid diagnosis of influenza has increased the demand for antiviral drugs.

The introduction of blockbuster therapeutics has further fueled market growth. Drugs like Biktarvy (Gilead Sciences) and Triumeq (GlaxoSmithKline) have revolutionized antiretroviral therapy, improving patient outcomes and treatment adherence. Biktarvy, approved in February 2024, targets populations living with HIV, where approximately 21 million people receive antiretroviral therapy, significantly strengthening immune systems.

Market Restraints

High costs of antiviral medications and limited access in developing countries pose barriers to widespread adoption. Additionally, the emergence of resistant viral strains requires ongoing R&D to develop next-generation therapies.

Market Segmentation

By Drug Class:

• Combination drugs dominate with a 63.32% share in 2026, driven by brands like Genvoya, Mavyret, and Triumeq.
• Integrase inhibitors are projected to expand due to potent drugs like Tivicay and Isentress, favored for high efficacy and tolerability.
• Other classes include protease inhibitors, polymerase inhibitors, reverse transcriptase inhibitors, and miscellaneous agents.

By Disease Indication:

• HIV dominates with an 82.04% share in 2026, owing to its high prevalence and supportive reimbursement policies.
• Other indications include hepatitis, influenza, herpes, rotavirus, and other viral infections. Government participation in HIV awareness and preventive programs also supports market growth.

By Distribution Channel:

• Hospital pharmacies dominate due to government support, favorable reimbursement, and organized supply networks.
• Retail pharmacies hold a 47.66% share in 2026, supported by OTC and generic antiviral availability.
• Online channels are projected to grow significantly due to increased accessibility and convenience.

Regional Analysis

North America: Revenue of USD 16.42 billion in 2025, led by U.S. market, driven by HIV prevalence, strong pharmaceutical presence, and approvals of blockbuster therapies. U.S. market projected to reach USD 14.22 billion by 2026.

Asia Pacific: Expected to show the highest CAGR, driven by improved pharmaceutical infrastructure in India and Japan, frequent viral outbreaks, and government participation in disease management. Markets in Japan, China, and India are projected at USD 1.86 billion, USD 2.72 billion, and USD 2.57 billion by 2026, respectively.

Europe: Market growth supported by favorable reimbursement, new product launches, and active government support. UK and Germany projected at USD 1.71 billion and USD 2.71 billion by 2026, respectively.

Latin America & Middle East/Africa: Growth driven by improved healthcare infrastructure, awareness campaigns, and government initiatives to address unmet needs for effective antiviral therapies.

Competitive Landscape

Key players include Gilead Sciences, GlaxoSmithKline, AbbVie, Merck & Co., Bristol-Myers Squibb, Janssen Pharmaceuticals, Mylan, and Novartis.

Notable Developments:

• July 2021: Vaxart, Inc. licensed Vapendavir to Altesa Biosciences for clinical-stage antiviral development.
• June 2021: Pardes Biosciences and FS Development merged to advance oral antivirals against SARS-CoV-2.
• March 2021: Pfizer initiated Phase 1 study for oral protease inhibitor PF-07321332 targeting SARS-CoV-2.
• January 2021: ViiV Healthcare received FDA approval for Cabenuva, reducing HIV treatment dosing from 365 to 12 days annually.

Conclusion

The antiviral drugs market is projected to grow from USD 42.34 billion in 2025 to USD 54.37 billion by 2034, at a CAGR of 3.64%. Market growth is primarily driven by the high prevalence of HIV and influenza, introduction of blockbuster drugs, and increasing government support for public health initiatives. Hospital pharmacies continue to dominate distribution, while emerging online channels enhance accessibility. North America maintains the largest market share, while Asia Pacific is expected to witness the highest growth due to expanding healthcare infrastructure and rising viral disease burden. The presence of established pharmaceutical players and robust pipeline developments are anticipated to shape the competitive landscape, ensuring continued growth in antiviral therapeutics worldwide.

Segmentation By Drug Class

• Protease Inhibitors
• Polymerase Inhibitors
• Integrase Inhibitors
• Reverse Transcriptase Inhibitors
• Combination Drugs
• Others

By Disease Indication

• Hepatitis
• Human Immunodeficiency Virus (HIV)
• Influenza
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Channel

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East and Africa (South Africa, GCC, and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Key Industry Trends
• 4.2. Recent industry developments such as mergers & acquisitions
• 4.3. regulatory and reimbursement scenario for key countries
• 4.4. Prevalence of Key viral diseases, in major countries, 2025
• 4.5. New Product Launches

5. Global Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Hepatitis
  • 5.2.2. Human Immunodeficiency Virus (HIV)
  • 5.2.3. Influenza
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Drug Class
  • 5.3.1. Integrase Inhibitors
  • 5.3.2. Polymerase Inhibitors
  • 5.3.3. Protease Inhibitors
  • 5.3.4. Combination Drugs
  • 5.3.5. Reverse Transcriptase Inhibitors
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Channel
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Disease Indication
  • 6.2.1. Hepatitis
  • 6.2.2. Human Immunodeficiency Virus (HIV)
  • 6.2.3. Influenza
  • 6.2.4. Others
• 6.3. Market Analysis - By Drug Class
  • 6.3.1. Integrase Inhibitors
  • 6.3.2. Polymerase Inhibitors
  • 6.3.3. Protease Inhibitors
  • 6.3.4. Combination Drugs
  • 6.3.5. Reverse Transcriptase Inhibitors
  • 6.3.6. Others
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Channel
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Disease Indication
  • 7.2.1. Hepatitis
  • 7.2.2. Human Immunodeficiency Virus (HIV)
  • 7.2.3. Influenza
  • 7.2.4. Others
• 7.3. Market Analysis - By Drug Class
  • 7.3.1. Integrase Inhibitors
  • 7.3.2. Polymerase Inhibitors
  • 7.3.3. Protease Inhibitors
  • 7.3.4. Combination Drugs
  • 7.3.5. Reverse Transcriptase Inhibitors
  • 7.3.6. Others
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Channel
• 7.5. Market Analysis - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Disease Indication
  • 8.2.1. Hepatitis
  • 8.2.2. Human Immunodeficiency Virus (HIV)
  • 8.2.3. Influenza
  • 8.2.4. Others
• 8.3. Market Analysis - By Drug Class
  • 8.3.1. Integrase Inhibitors
  • 8.3.2. Polymerase Inhibitors
  • 8.3.3. Protease Inhibitors
  • 8.3.4. Combination Drugs
  • 8.3.5. Reverse Transcriptase Inhibitors
  • 8.3.6. Others
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Channel
• 8.5. Market Analysis - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Disease Indication
  • 9.2.1. Hepatitis
  • 9.2.2. Human Immunodeficiency Virus (HIV)
  • 9.2.3. Influenza
  • 9.2.4. Others
• 9.3. Market Analysis - By Drug Class
  • 9.3.1. Integrase Inhibitors
  • 9.3.2. Polymerase Inhibitors
  • 9.3.3. Protease Inhibitors
  • 9.3.4. Combination Drugs
  • 9.3.5. Reverse Transcriptase Inhibitors
  • 9.3.6. Others
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Channel
• 9.5. Market Analysis - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Disease Indication
  • 10.2.1. Hepatitis
  • 10.2.2. Human Immunodeficiency Virus (HIV)
  • 10.2.3. Influenza
  • 10.2.4. Others
• 10.3. Market Analysis - By Drug Class
  • 10.3.1. Integrase Inhibitors
  • 10.3.2. Polymerase Inhibitors
  • 10.3.3. Protease Inhibitors
  • 10.3.4. Combination Drugs
  • 10.3.5. Reverse Transcriptase Inhibitors
  • 10.3.6. Others
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Channel
• 10.5. Market Analysis - By Country/Sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2018)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.5.1. Gilead Sciences
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. GlaxoSmithKline
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Abbvie, Inc.
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Merck & Co., Inc.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Bristol-Myers Squibb Company
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Janssen Pharmaceuticals, Inc.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Mylan N.V.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Novartis AG
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)

12. Strategic Recommendations